Last reviewed · How we verify
NCT07107373
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
trial testing Mavacamten in Obstructive Hypertrophic Cardiomyopathy (oHCM) in 150 participants. Participants enrolled and being followed up; not accepting new ones.
26 July 2024
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 22 December 2023 |
| Primary completion | 26 July 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Mavacamten (MAVACAMTEN) — full drug profile →
Conditions studied
- Obstructive Hypertrophic Cardiomyopathy (oHCM) — all drugs for Obstructive Hypertrophic Cardiomyopathy (oHCM) →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
18 and older, any sex, with Obstructive Hypertrophic Cardiomyopathy (oHCM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy.
Ferraresi B, Nenna A, Jawabra M, Corrado D, et al · · 2026 · PMID 42188073 · DOI 10.3390/jcdd13050187
Verify or expand the search:
- PubMed search for NCT07107373
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mavacamten
Trials testing the same drug.
- NCT07361289 — A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopa · recruiting
- NCT07004972 — A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER) · Phase 4 · recruiting
- NCT07383025 — Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan · recruiting
- NCT06856265 — Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardi · NA · not yet recruiting
- NCT06146660 — A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy · recruiting
Other recruiting trials for Obstructive Hypertrophic Cardiomyopathy (oHCM)
Currently open trials in the same condition.
- NCT07367724 — Ademetionine in Obstructive Hypertrophic Cardiomyopathy · Phase 2 · recruiting
- NCT07383025 — Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan · recruiting
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07107373 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07107373.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing